Why Island Pharmaceuticals (ASX:ILA) Shares Are Trading Higher On Tuesday?

Highlights

• Island Pharmaceuticals shares rose 26.67% on 7 July 2026 after announcing government and regulatory approvals for Galidesivir use in Uganda.

• The company has secured approvals for compassionate use of Galidesivir under the WHO-recognised MEURI emergency clinical framework.

• The program targets the ongoing Bundibugyo Ebola epidemic, which has recorded more than 1,480 confirmed cases and about 450 deaths.

• Island said the program is funded by government and supporting institutions, with its contribution limited to supplying Galidesivir.

• Galidesivir is expected to be deployed within CY26, supported by the company’s recent GMP manufacturing campaign.

Island Pharmaceuticals Limited (ASX:ILA) shares climbed 26.67% to AUD 0.48 during the morning session on 7 July 2026 after the company announced that all government, regulatory and ethics approvals had been secured for the compassionate use of Galidesivir during the ongoing Bundibugyo Ebola epidemic in Uganda. The stock remains up 179.41% over the past year, with today’s sharp move following a favourable update that gives Island an opportunity to generate prospective human data during an active Ebola outbreak.

Island Pharmaceuticals is an Australian antiviral drug development company focused on urgent viral diseases, public health threats and biosecurity-related medical needs. The company is progressing a dual development strategy across ISLA-101 and Galidesivir. ISLA-101 is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases, while Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity across more than 20 RNA viruses, including Ebola, Marburg, MERS, Zika and Yellow fever.

Government Approvals Create Emergency Use Pathway

The latest update centres on Galidesivir, Island’s broad-spectrum antiviral candidate. The company has secured all required regulatory and ethics approvals to enable compassionate use treatment for infected patients during the current Bundibugyo Ebola outbreak in Uganda.

The treatment will be made available under the Monitored Emergency Use of Unregistered and Investigational Interventions framework, commonly known as MEURI. This framework is recognised by the World Health Organization and is designed for public health emergencies where no approved treatment options exist and conventional randomised clinical trials may not be practical or ethical.

Under the approved program, eligible patients will receive Galidesivir during the current and potential subsequent outbreaks. Investigators will prospectively collect clinical, safety and virological data under an approved protocol. This gives Island a rare opportunity to generate human data in the intended disease setting while also supporting emergency patient access.

Bundibugyo Ebola Outbreak Highlights Urgent Treatment Gap

Island said the Bundibugyo Ebola epidemic continues to escalate across multiple African countries, including Uganda and the Democratic Republic of Congo. As of 6 July 2026, the outbreak had recorded 1,481 confirmed cases and 454 deaths, with a case fatality rate of 31%.

The company also noted that more than 70 new cases are being reported daily, with the outbreak spreading into additional provinces. Emergency public health measures have been implemented in Kinshasa, the densely populated capital of the Democratic Republic of Congo, which has a population of more than 15 million people.

The update also highlighted a separate Marburg virus fatality in Uganda, creating what Island described as a rare dual-pathogen event. The presence of both Ebola and Marburg virus activity adds significance to antiviral candidates with potential activity across multiple filoviruses.

There are currently no approved therapeutics or vaccines for Bundibugyo Ebola or Marburg virus, according to Island. This unmet need is central to the company’s rationale for deploying Galidesivir under the emergency framework.

Galidesivir to Generate Real-World Human Data

The approved MEURI program allows Galidesivir to be evaluated in real-world patients during an active Ebola outbreak. Unlike standard compassionate use programs, MEURI requires structured data collection, including predefined clinical assessments, safety monitoring and outcome measures.

This means the program may produce prospective human efficacy, safety and virological information while patients receive treatment during the outbreak. Island said this data could support Galidesivir’s broader development package alongside previous non-human primate studies and ongoing regulatory work.

The company stated that Galidesivir has previously demonstrated 100% survival in Galidesivir-treated Ebola Zaire-infected non-human primates, compared with 0% survival in placebo-treated controls. It also said Galidesivir has cell culture or non-human primate efficacy data across Ebola, Marburg and Sudan viruses.

Non-Dilutive Program Supports Capital-Efficient Development

A key investor-focused point in the announcement is that the MEURI program is sponsored by the Uganda Ministry of Health and supported by the World Health Organization and African infectious disease institutions.

Island said the program is fully funded by government and supporting institutions, with the company’s role limited to supplying Galidesivir. This creates a non-dilutive development opportunity, as the company can participate in an active clinical deployment without carrying the full cost burden of a conventional trial.

The program follows more than 12 months of collaboration between Island and the ACCEPT-Africa Consortium, which initially focused on clinical capability and outbreak preparedness. Once the current Bundibugyo Ebola outbreak emerged, the collaboration moved from planning into implementation of the approved MEURI protocol.

GMP Manufacturing Supports Planned Deployment

Island is now working with its partner network to supply GMP-grade Galidesivir to participating treatment sites. The company said its recently executed GMP manufacturing campaign supports readiness for clinical deployment in response to emerging viral outbreaks.

Galidesivir is expected to be deployed within CY26. Island is also working on an additional acceleration pathway that may allow the drug to become available for compassionate use before the end of CY26.

This manufacturing readiness is important because emergency outbreak response depends on rapid availability of clinical-grade material, particularly when case numbers are increasing and treatment options are limited.

Dual Development Pathway Strengthens Strategic Position

Island said Galidesivir is now moving through two potentially complementary FDA-aligned development pathways. The first pathway involves real-world human clinical data generated through MEURI use in Bundibugyo Ebola patients. The second pathway involves controlled non-human primate efficacy studies under the FDA Animal Rule, including ongoing pivotal Marburg studies.

The company’s primary regulatory pathway remains the FDA Animal Rule, but the MEURI program provides an additional route to collect human data in the intended disease setting.

Island also noted that the regulatory approach has similarities with the pathway used by the two FDA-approved Ebola therapeutics, Ebanga and Inmazeb, which were approved based on moderate efficacy supported by real-world outbreak data. Since approval, those products have generated more than US$1 billion in government procurement and Strategic National Stockpile orders, according to the company.

Management Sees Important Milestone for Galidesivir

Chief Executive Officer and Managing Director Dr David Foster said securing the approvals marks a significant milestone for Galidesivir and reflects more than a year of collaboration with partners in Uganda and the ACCEPT-Africa Consortium.

He said the approval decision followed a rigorous scientific and ethical review process involving Uganda’s regulatory and public health authorities. He also noted that the current Bundibugyo Ebola outbreak highlights the need for new antiviral treatment options, given the absence of approved therapeutics for Bundibugyo Ebola or Marburg virus.

Dr Foster said the MEURI framework provides the first opportunity to evaluate Galidesivir in real-world infected patients while prospectively collecting clinical, safety and virological data.

Investor Webinar Scheduled

Island will host an investor webinar at 11:00am AEST, or 9:00am AWST, on Wednesday, 8 July CY26. CEO and Managing Director Dr David Foster and Non-Executive Chairman Jason Carroll will provide further details on the in-human trial opportunity in Africa, broader biodefence engagement and other near-term opportunities.

What This Means for Investors

Island Pharmaceuticals’ latest update represents a notable development for Galidesivir, as the company has secured approvals to use the antiviral candidate in an active Ebola outbreak setting. The announcement is favourable because it gives Island access to prospective human clinical, safety and virological data while limiting its financial contribution to drug supply. With the program funded by government and supporting institutions, and Galidesivir also progressing through the FDA Animal Rule pathway, investors are likely watching how quickly deployment occurs and what data emerges from the MEURI program.